SWITCHING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FROM BEVACIZUMAB TO RANIBIZUMAB: Who is Likely to Benefit From the Switch?
| Autor: | Gabriel Katz, Hana Levkovitch-Verbin, Joseph Moisseiev, Elad Moisseiev, Anat Loewenstein, Yosef Lomnicky, Michaella Goldstein, Dafna Goldenberg, Yitzhak Abend, Giora Treister |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Vascular Endothelial Growth Factor A medicine.medical_specialty Visual acuity genetic structures Bevacizumab Visual Acuity Angiogenesis Inhibitors Retina chemistry.chemical_compound Age related Ophthalmology Ranibizumab medicine Humans Aged Retrospective Studies Aged 80 and over business.industry Drug Substitution Retinal Retrospective cohort study General Medicine Macular degeneration Middle Aged VISUAL ACUITY DECREASE medicine.disease eye diseases chemistry Intravitreal Injections Wet Macular Degeneration Female sense organs medicine.symptom business Tomography Optical Coherence medicine.drug |
| Zdroj: | Retina (Philadelphia, Pa.). 35(7) |
| ISSN: | 1539-2864 |
| Popis: | Purpose: To evaluate the safety and efficacy of switching from bevacizumab to ranibizumab in patients with neovascular age-related macular degeneration. Methods: Retrospective study of patients with neovascular age-related macular degeneration initially treated with bevacizumab and switched to ranibizumab. Visual acuity and central retinal thickness (CRT) were retrieved at four time points: before the last three bevacizumab injections, at the switch, after the first three ranibizumab injections, and at the end of follow-up. Results: One hundred and fourteen eyes of 110 patients were included. Switching from bevacizumab to ranibizumab did not achieve a significant change in visual acuity, and a significant reduction in CRT was achieved after the first three injections but was not maintained by the end of follow-up. Eyes that lost ≥0.1 logMAR before the switch were more likely to improve in visual acuity (P = 0.013), and eyes with ≥10% increase in CRT before the switch were more likely to improve anatomically (P = 0.0003). In 47.3% of the eyes, the CRT was reduced by ≥10% after the first 3 ranibizumab injections, and the reduction was maintained with additional injections. Conclusion: Switching to ranibizumab should be considered in patients with visual acuity decrease or CRT increase, despite monthly bevacizumab injections. The response should be evaluated after the first three injections to guide future treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|